FLUXID SUMMARY
FLUXID™
(FAMOTIDINE ORALLY DISINTEGRATING TABLETS)
FLUXID™ (famotidine orally disintegrating tablets) is a histamine H2-receptor antagonist. Famotidine is N′ -(aminosulfonyl)-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio] propanimidamide.
FLUXID™ is indicated in:
1. Short term treatment of active duodenal ulcer. Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks.
2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. Controlled studies in adults have not extended beyond one year.
3. Short term treatment of active benign gastric ulcer. Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks.
4. Short term treatment of gastroesophageal reflux disease (GERD). FLUXID™ is indicated for short term treatment of patients with symptoms of GERD (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies).
FLUXID™ is also indicated for the short term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies).
5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas) (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies).
|
NEWS HIGHLIGHTS
Published Studies Related to Fluxid (Famotidine)
Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. [2009.07.11]
BACKGROUND: There are few therapeutic options for the prevention of gastrointestinal mucosal damage caused by low-dose aspirin. We therefore investigated the efficacy of famotidine, a well-tolerated histamine H(2)-receptor antagonist, in the prevention of peptic ulcers and erosive oesophagitis in patients receiving low-dose aspirin for vascular protection... INTERPRETATION: Famotidine is effective in the prevention of gastric and duodenal ulcers, and erosive oesophagitis in patients taking low-dose aspirin. These findings widen the therapeutic options for the prevention of gastrointestinal damage in patients needing vascular protection. FUNDING: Merck Laboratories and Astellas Pharma.
Early effects of intravenous administrations of lansoprazole and famotidine on intragastric pH. [2009.03]
CONCLUSIONS: In Helicobacter pylori-negative healthy male subjects, an intravenous dose of famotidine 20 mg more rapidly increases intragastric pH than lansoprazole 30 mg.
Can famotidine and omeprazole be combined on a once-daily basis? [2007.06]
CONCLUSIONS: Compared with treatment with omeprazole alone, on day 1 famotidine and omeprazole in combination improved the duration of and time to reach intragastric pH > 4. With regard to duration with pH > 4, the combination therapy was superior to famotidine alone on day 8. The rapid acid control with an H2-receptor antagonist may be combined with the long-lasting antisecretory effect of a proton-pump inhibitor.
Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers. [2007.02]
Low-dose omeprazole is superior to full-dose famotidine in maintenance therapy for gastroesophageal reflux disease, whereas "on-demand" famotidine is more effective for relief of episodes of heartburn. To explain this apparent discrepancy, intragastric pH was measured for 24-hr seven times in eight Japanese Helicobacter pylori-negative cytochrome P450 2C19 extensive metabolizers; on Days 1, 8, and 15 of repeated administration of 10 mg of omeprazole once daily and of 20 mg of famotidine twice daily and before medication...
Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. [2006.11]
BACKGROUNDS AND AIMS: Faster and stronger acid inhibition is required for the treatment of hemorrhage from peptic ulcers. We compared the effects of intravenous infusion regimens of a proton pump inhibitor (PPI) alone, a histamine 2 receptor antagonist (H2RA) alone, and the combination of a PPI with an H2RA on acid inhibition in the early postadministration phase in relation to cytochrome P450 (CYP) 2C19 genotype status... CONCLUSIONS: For faster and stronger acid inhibition, the concomitant infusion regimen of a PPI and an H2RA appears to be therapeutically useful in homozygous and heterozygous EMs, but omeprazole alone appears to be sufficient in poor metabolizers of CYP2C19.
Clinical Trials Related to Fluxid (Famotidine)
Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir [Completed]
The purpose of this clinical research study is to assess the pharmacokinetics of atazanavir,
identifying one or more dosing regimens of atazanavir/ritonavir/tenofovir when dosed with
famotidine results in atazanavir exposures similar to those when
atazanavir/ritonavir/tenofovir 300/100/300 mg is dosed without famotidine in healthy
subjects.
Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients [Completed]
The purpose of this clinical research study is to assess the effect of Famotidine given twice
daily on Atazanavir administered with Ritonavir in HIV-Infected subjects.
Ulcer Prevention Study in Post Gastric Bypass Patients [Active, not recruiting]
This research is to determine which medication, Zegerid (Omeprazole/Sodium Bicarbonate) or
Pepcid AC (Famotidine), works best at reducing the chance that a patient will get an ulcer
after gastric bypass surgery.
Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia [Recruiting]
Aspirin can prevent ischemic vascular disease but is commonly complicated by dyspepsia in
30% of patients. Patients, who have aspirin related dyspepsia, commonly underwent upper
endoscopy to exclude peptic ulcer disease or gastric cancers. For those without significant
lesions in the stomach and duodenum (non-ulcer dyspepsia), the best approach in the
management is unclear. The objective of this study is to compare the efficacy of
esomeprazole and famotidine in the control of dyspeptic symptom. After giving consent,
patients will be randomised to receive either esomeprazole 20 mg daily or famotidine 40 mg
daily in a double blinded manner. The patient will be followed-up at the 2nd and 4th week.
The study will be completed at the 4th week. The primary analysis will be the efficacy in
the control of dyspepsia symptom between the two groups.
Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis [Recruiting]
Although stress ulcer is a complication that can cause significant mortality and morbidity
in critical patients with risk factors, there is still lack of consensus about its
prophylaxis. There are also few data available from Taiwan. H2 blockers are commonly used
due to convenience. Some prefer sucralfate (a mucosal protective agent) for the sake of less
association with nosocomial pneumonia. Recently, proton pump inhibitors were shown to have
good prophylactic effects for stress ulcer. Pantoprazole (iv) is the first intravenous form
of proton pump inhibitor that was approved by FDA. There are some reports about its
application for treatment of peptic ulcer bleeding. It also has good acid suppression effect
in patients under critical care. We expect that intravenous pantoprazole will have a role in
stress ulcer prophylaxis.
We will enroll those patients that have received major abdominal surgery and admitted to
surgical ICU. After obtaining the consent, we will give them prophylactic drugs for 7 days
within 24 hours. They are randomly allocated to 2 groups. Group I: pantoprazole 40 mg iv
bolus stat and then qd ; Group II: famotidine 20 mg iv bolus stat and then q12h. We will
monitor the following data: operation type & time, APACHE II score, CBC, CXR, stool
character and OB test, NG aspirate. If clinical evidence of UGI bleeding occurs, endoscopic
examination will be performed. We define the end point as overt bleeding, death or transfer
out of ICU. We will compare the prevalence of UGI bleeding and ventilator associated
pneumonia in these 2 groups
|
|
|
|
Page last updated: 2009-10-20
|
